The efficacy and safety of bucillamine as a second-line DMARD in the treatment of rheumatoid arthritis: a retrospective cohort study |
| |
Authors: | Akiko Suda Shouhei Nagaoka Shigeru Ohono Haruko Ideguchi Takayoshi Soga Yoshiaki Ishigatsubo |
| |
Institution: | (1) Department of Rheumatology, Yokohama Minami Kyosai Hospital, 1-21-1 Mutsuurahigashi, Kanazawa-ku, Yokohama Kanagawa, 236-0037, Japan;(2) Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama Kanagawa, 236-0004, Japan |
| |
Abstract: | We investigated the efficacy and safety of bucillamine administered as a second-line DMARD compared to administration as a
first-line DMARD in the treatment of rheumatoid arthritis (RA). We conducted a retrospective cohort study and reviewed medical
records of 86 patients with active RA who began to receive bucillamine at Yokohama Minami Kyosai Hospital between January
1998 and July 2004. The efficacy of treatments was compared based on rates of achievement of 20, 50, and 70% improvement in
ACR core set 6 months after initiation of the therapy. In the group administered bucillamine as a first-line DMARD (18 patients),
44.4, 22.2, and 11.1% of patients achieved ACR 20, 50, 70, respectively, while 56.5, 34.1, and 19.5% achieved ACR 20, 50,
70, respectively, in the group administered bucillamine following switching from MTX (46 patients), and 53.3, 33.3, and 13.3%
achieved ACR 20, 50, and 70, respectively, in the group administered bucillamine following switching from Sulfasalazine (SSZ)
(15 patients). The rates of achievements of ACR 20, 50, 70 did not differ statistically between the three groups and there
was no increase in risk of serious adverse effects related to previous DMARDs. The usefulness of bucillamine as a second-line
DMARD was demonstrated. |
| |
Keywords: | Bucillamine DMARD MTX Sulfasalazine Switching therapy Rheumatoid arthritis |
本文献已被 PubMed SpringerLink 等数据库收录! |
|